This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
In their well-controlled study demonstrating the increased frequency of histocompatibility (HL-A) antigens W16 and W17 in patients with psoriasis, Krulig et al (Arch Dermatol 111:857, 1975) made the statement: "The increased frequency of the W16 and the W17 antigens in patients (with psoriasis) suggests that persons possessing these antigens are at an increased risk of psoriasis." Although it is of interest that these antigens were more common in psoriatics, it does not necessarily follow that the prevalence of psoriasis among persons possessing W16 and W17 antigens is increased. We can only regard their "suggestion" as an intriguing hypothesis and must await a study of populations possessing W16 and W17 antigens. Specifically, their report does not warrant telling a concerned person who possesses W16 and W17 antigens that he has an increased risk of developing clinical psoriasis.
Residents' Journal Club. Histocompatibility (HL-A) Antigens and Psoriasis. Arch Dermatol. 1976;112(7):1030. doi:10.1001/archderm.1976.01630310076020
Customize your JAMA Network experience by selecting one or more topics from the list below.